Figure 1

ATG5^Mye−/− mice show enhanced DEN-induced hepatocarcinogenesis. (A) Left, liver weight; Right, liver/body weight ratio of WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. n = 28 for WT mice Control; n = 26 for ATG5^Mye−/− mice Control; n = 50 for WT mice DEN; n = 50 for ATG5^Mye−/− mice DEN. (B) Left, livers of WT or ATG5^Mye−/− mice 10 months after DEN treatment; Right, tumor number and tumor volume in WT or ATG5^Mye−/− mice 10 months after DEN treatment. n = 41 for WT mice DEN; n = 40 for ATG5^Mye−/− mice DEN. (C) Representative PCNA staining (magnification × 200) and quantification of PCNA-positive cell per field in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. n = 9 for WT mice Control; n = 6 for ATG5^Mye−/− mice Control; n = 10 for WT mice DEN; n = 10 for ATG5^Mye−/− mice DEN. (D) RT-PCR analysis of AFP and CD133 mRNA (left panel) and serum AFP levels (right panel) in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution injection. n = 9 for WT mice Control; n = 6 for ATG5^Mye−/− mice Control; n = 21 for WT mice DEN; n = 26 for ATG5^Mye−/− mice DEN. Data are shown as mean ± SEM. *p < 0.05 for WT Control vs WT DEN, # for ATG5^Mye−/− Control vs ATG5^Mye−/− DEN and ^&p < 0.05 for WT vs ATG5^Mye−/−.